Objective. To assess aetiology of a POF in a 33-year-old woman and, if possible, plan a cure. Design. Case report. Setting. medical genetics diagnostic unit in a university hospital. Patient. A 33-year-old woman with premature ovarian failure (POF).
Introduction
e average of age of the menopause is 50 years [1] with one percent of women menstruating aer the age of 60 and one percent entering menopause before the age of 40.
Hereditary and environmental (smoking habit) factors affect the age of the natural menopause. A menopause before the age of 40 is commonly de�ned as "premature ovarian failure" although this de�nition is arbitrary. Estimates of the prevalence of premature ovarian failure range between 0.3 and 1% and this condition accounts for 10-28% of women with primary amenorrhoea and 4-18% of women with secondary amenorrhoea [2] (Table 1) .
Some of the causes of POF listed above are extremely rare-particularly the genetic causes. For instance only a few women with FSH-receptor or LH-receptor mutations have ever been reported. In order to give an idea of how common various conditions are, here is a list of the causes of POF in women attending a specialist clinic at the Middlesex Hospital, London, UK (Table 2) .
10 to 30% of women with POF already have a concurrent autoimmune disorder the most common of which is hypothyroidism. In the sequence of the most common autoimmune associations found in APSII, ovarian failure can occur at any stage. us, a history should include symptoms of Addison's disease, hypothyroidism, and diabetes in particular with the rarer association of autoimmune arthitides and in�ammatory bowel disease being kept in mind. Further, women with established POF should be monitored for the later appearance of these conditions. e only features of history which are helpful in determining aetiology of ovarian failure are positive a family history, a concurrent autoimmune disorder, or stigmata of one of the inherited conditions. In many instances a formal pedigree enquiry is required to determine other female family members who may be affected, particularly if the inheritance is passed through an unaffected male.
Case Presentation
A 33-year-old woman affected by hypergonadotropic hypogonadism (FSH 71.38 mIU/L; LH 35.50 mIU/L; estradiol <7 pg/mL) had been treated with estroprogestinic therapy "Triminulet" for nine years. Treatment was then suspended to allow a reevaluation of ovarian functionality. Upon drug withdrawal the patient presented secondary amenorrhea and was referred to our unit for an indepth diagnostic evaluation. A written informed consent was obtained.
Medical history revealed that the patient was born with normal delivery, bottle-fed, and showed standard psychosomatic development, menarche at age of 13 and oligomenorrhea since then up until estroprogestinic therapy was established. Pelvic US demonstrated a normally placed and A blood sample was drawn in Sodium (Na) heparin coated tube (vacutainer) for mononuclear cells culture and GTG karyotyping. High-de�nition GTG banding analysis of 100 metaphases (Leica CW4000 soware) demonstrated a 45,X (41%)/46,X,rea(X) (59%) mosaicism (Figure 2) .
CBG staining of a new lymphocyte preparation demonstrated the presence of two centromeres in the X rearranged population [46,X,rea(X)] (Figure 3) . Finally FISH analysis (kit ToTelVysion (TM) Multicolor DNA probe mixtures (Vysis) ), con�rmed the presence of two X centomeres in rearranged X chromosomes with 2 Xp extremities and no Xq extremity. In the rearranged X chromosome the Xq extremity was substituted by Xp and pericentrometric Xq region. Aer Aer a written informed consent was obtained from �rst degree relatives of our patient (parents and sister), a GTG karyotype analysis extended to family members demonstrated that the phenotype observed in our patient was the result of a de novo alteration.
Discussion
Turner's syndrome accounts for most of the cases of nonidiopathic premature ovarian failure [3]. Turner's syndrome is a syndrome of defective gonadal development in phenotypic females mostly associated with the karyotype 45,X. Patients generally present short stature with gonadal dysgenesis (streak gonads), webbing of the neck, cubitus valgus, elevated gonadotropins, decreased estradiol level in blood, hypothyroidism, congenital heart defects, and primary amenorrhoea with failure to develop secondary sex characteristics (sexual infantilism) [4] .
Mosaicisms accounts for 35% of Turner syndrome cases. 10% of these cases are due to mosaicisms for an X isochromosome [5] . Typically, in case of mosaicism, patients may present features that do not satisfy all the characteristics of the syndrome.
e case examined in the paper shows an attenuated phenotype, consistent with an X chromosome mosaicism. Indeed 41% cells have a monosomy of the X chromosome (45,X karyotype). e remaining 59% cells have an isodicentric X chromosome, then presenting a trisomy of Xp, monosomy of Xq24, and partial trisomy of the rest of Xq.
is can explain the atypical phenotype of the patient: even in absence of classical dysmorphic features (pterigio, typical facies, and primary amenorrhea), she still suffers from other peculiar endocrine alterations, like hypergonadotropic hypogonadism, hypothyroidism, and autoimmune phenomena. Regarding primary amenorrhea, this is not present in our case, although she has undergone to a premature ovarian failure.
Interestingly menarche and ovarian function are essentially regulated by two genes on X chromosome: POF1 and POF2, respectively, located on Xq24-Xq28 and Xq21.33. Based on our karyotype analysis we can say that, in the subpopulation of rearranged X chromosomes, POF1 results deleted, whereas POF2 is present in three copies.
�e hypothesi�e that this peculiar genetic con�guration can be sufficient to induce menarche, although POF1 haploinsufficiency is probably inadequate to sustain ovarian function thus leading to secondary amenorrhea.
Another trait typical of Turner's syndrome is short stature. In this case, patient's stature is in the lower normal range, included between the 3 and the 25 percentile. e SHOX gene is made of seven exons, one of which is noncoding. Homeobox domain is coded by exons 3 and 4, that acts like transcriptional activators. SHOX codes also two alternatively spliced transcripts, SHOXa and SHOXb. e SHOX gene act during early embryonic development to control the formation of many body structures. Speci�cally, the SHOX gene is essential for the development of the skeleton and plays an important role in growth [6] [7] [8] and maturation of bones in the arms and legs.
One copy of the SHOX gene is located on each of the sex chromosomes (the X and Y chromosomes) in an area called the pseudoautosomal region, Xp22.33 and Yp11.3 ( Figure 5 ). Although many genes are unique to either the X or Y chromosome, genes in the pseudoautosomal region are present and are transcriptionally active on both chromosomes. As a result, females (who have two X chromosomes) and males (who have one X and one Y chromosome) have two functional copies of the SHOX gene in each cell.
Because the SHOX gene is located on the sex chromosomes, most women with Turner syndrome have only one copy of the gene in each cell instead of the usual two copies. Loss of one copy of this gene reduces the amount of SHOX protein that is produced. A shortage of this protein likely contributes to the short stature and skeletal abnormalities [9] oen seen in females with Turner syndrome [10].
In the case described in the present paper, SHOX gene is triplicated in the cell subpopulation harboring the rearranged X chromosome and this triplication can probably in part correct the haploinsufficiency that is present in the 45,X cells [11] thus mitigating the short stature phenotype that is typical of Turner syndrome.
